Bausch Health Responds to Market Rumors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies on Bausch Health Companies (BHC): 'Another Case of Irresponsible Journalism Wreaks Havoc in Shares'
July 24, 2024 3:43 PM EDTJefferies analyst Glen Santangelo reiterated a Buy rating and $13.00 price target on Bausch Health Companies (NYSE: BHC)
The analyst comments "This morning, a report from Reorg comments that BHC was negotiating a pre-packaged Chap 11 bankruptcy filing. BHC has since commented this is NOT true. This reminds us of the April Wall St Journal article that insinuated that one of Zoetiss drugs (Librela) was killing dogs! Both situations were unfounded. Unfortunately,... More
